LY2880070 Clinical Trials

Size	Price	Qty
5mg	USD 147
25mg	USD 447

Clinical Trials

Multiple completed clinical trials sponsored by Memorial Sloan Kettering Cancer Center and Esperas Pharma Inc. have evaluated the safety and therapeutic potential of LY2880070 across Phase 1 and Phase 2. A Phase 2 study investigated LY2880070 combined with low-dose gemcitabine in patients with relapsed or refractory Ewing sarcoma and Ewing-like sarcoma. Additionally, a Phase 1b/2a trial evaluated the compound as monotherapy and combination therapy across solid tumors, including colorectal, pancreatic, endometrial, ovarian, and triple-negative breast cancers.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT05275426	COMPLETED	Ewing Sarcoma; Ewing-Like Sarcoma	Memorial Sloan Kettering Cancer Center	2022-03-02	PHASE2
NCT02632448	COMPLETED	Solid Tumors; Colorectal Cancer; Breast Cancer; Ovarian Cancer; Colon Cancer; Rectal Cancer; Neoplasms; Endometrial Cancer; Soft Tissue Sarcoma; Triple Negative Breast Cancer; Pancreas Cancer; Pancreatic Cancer	Esperas Pharma Inc.	2016-05-16	PHASE1; PHASE2

(data from https://clinicaltrials.gov, updated on 2025-08-15)

Check the LY2880070 product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

LY2880070 selectively binds to and inhibits checkpoint kinase 1 (CHK1), which disrupts DNA damage checkpoint signalling and prevents cancer cells from repairing DNA lesions. This failure of checkpoint arrest forces compromised cells into premature and uncoordinated mitosis, inducing mitotic catastrophe and programmed cell death to inhibit tumor growth in clinical indications such as Ewing sarcoma and various advanced solid tumors.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).